Adaptive Biotechnologies Intrinsic Value Calculator – Adaptive Biotechnologies Achieves MRD Success Despite Challenging Market Conditions
December 16, 2023
☀️Trending News
Adaptive Biotechnologies ($NASDAQ:ADPT) has achieved great success in a challenging market landscape due to their breakthrough minimal residual disease (MRD) technology. The company offers a portfolio of products and services that have been proven to revolutionize diagnosis and treatment of cancer and other diseases. Through its AI-powered platform, Adaptive Biotechnologies has helped millions of patients improve their health outcomes and quality of life. Adaptive Biotechnologies is a leading biotechnology company that specializes in genomic sequencing, computational biology, and immunology. Their mission is to accelerate the development of scientific understanding and personalized medicine through the use of large-scale genomic sequencing.
In addition, Adaptive Biotechnologies has created the first FDA-approved advanced molecular diagnostic test for MRD, enabling physicians to identify the presence of cancer and other diseases at the earliest stages. The success of Adaptive Biotechnologies can be attributed to its cutting-edge technology and innovative approach to medicine. Through its platform, Adaptive Biotechnologies has enabled physicians to accurately diagnose a variety of diseases with greater speed and accuracy than ever before. This has enabled healthcare providers to quickly make decisions that can save lives, reduce hospital stays, and improve patient outcomes. With a focus on innovation and customer success, Adaptive Biotechnologies is continuing to make strides in improving healthcare for patients around the world.
Share Price
Adaptive Biotechnologies‘ stock opened at $5.2 on Friday and closed at $4.9, a drop of 6.0% from its prior closing price. This is despite the company’s considerable success in the minimal residual disease (MRD) market, which has been particularly difficult to navigate in the current climate. The company has been able to maintain its foothold in the MRD market due to its innovative products and services, which have been well received by the medical community.
Adaptive Biotechnologies has also made strong investments in research and development to stay ahead of the competition. As a result, it has been able to remain competitive despite challenging market conditions. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Adaptive Biotechnologies. More…
| Total Revenues | Net Income | Net Margin |
| 179.69 | -195.94 | -109.0% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Adaptive Biotechnologies. More…
| Operations | Investing | Financing |
| -159.41 | 28.9 | 2.16 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Adaptive Biotechnologies. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 717.68 | 356.05 | 2.5 |
Key Ratios Snapshot
Some of the financial key ratios for Adaptive Biotechnologies are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 24.8% | – | -101.1% |
| FCF Margin | ROE | ROA |
| -95.4% | -30.0% | -15.8% |
Analysis – Adaptive Biotechnologies Intrinsic Value Calculator
At GoodWhale, we recently conducted an analysis of ADAPTIVE BIOTECHNOLOGIES‘ wellbeing. Our proprietary Valuation Line was used to calculate the intrinsic value of the company’s share, which we determined to be around $21.8. Currently, the ADAPTIVE BIOTECHNOLOGIES stock is traded at $4.9, meaning it is undervalued by 77.5%. This presents a great opportunity for investors to capitalize on the stock and get a great return on their investment. More…
Peers
Adaptive Biotechnologies Corp is a biotechnology company that develops products to diagnose and treat cancer and other diseases. The company’s products are based on its proprietary technology platforms, which enable the company to identify and target cancer cells and other diseased cells. The company’s products include diagnostic tests and treatments for cancer, autoimmune diseases, and infectious diseases.
The company’s main competitors are Forte Biosciences Inc, Synaptogenix Inc, and Resverlogix Corp.
– Forte Biosciences Inc ($NASDAQ:FBRX)
Forte Biosciences Inc is a clinical-stage biopharmaceutical company that focuses on the development of therapeutics to improve patient outcomes in dermatology and immunology. The company’s lead product candidate is Vixari, a topical formulation of an anti-TNF-alpha biologic, which is in Phase 2 clinical trials for the treatment of plaque psoriasis. Forte Biosciences has a market cap of 20.95M as of 2022 and a Return on Equity of -42.75%. The company’s focus on developing therapeutics to improve patient outcomes in dermatology and immunology makes it a promising investment opportunity in the healthcare sector.
– Synaptogenix Inc ($NASDAQ:SNPX)
Synaptogenix is a clinical-stage biotechnology company developing drugs to treat neurodegenerative diseases. The company’s lead product candidate, SYN-115, is in development for the treatment of Alzheimer’s disease. Synaptogenix has a market cap of $43.23 million as of 2022 and a return on equity (ROE) of -38.9%. The company’s clinical-stage drugs are not yet approved for commercial use, which makes it a high-risk investment. However, the potential rewards for investors are significant if Synaptogenix is successful in developing an effective treatment for Alzheimer’s disease.
– Resverlogix Corp ($TSX:RVX)
Resverlogix Corp. is a biopharmaceutical company, which engages in the development of small molecule therapeutics for the treatment of atherosclerosis and associated diseases. Its products include RVX-208, RVX-210, and BETonMACE. The company was founded by Norman W. Wong on February 3, 2004 and is headquartered in Calgary, Canada.
Summary
Adaptive Biotechnologies has recently seen its stock price move down drastically, which is a clear indication that investors have become increasingly skeptical about the future performance of the company. Despite the challenging market conditions, the company has been successful in achieving milestones such as introducing new products and expanding its customer base.
However, investors remain uncertain about the company’s long-term prospects, given the competitive landscape in the biotech field. Furthermore, there is also a concern that new product introductions may fail to generate significant returns. Investors should keep a close eye on Adaptive Biotechnologies and monitor any progress made in terms of new product launches and customer acquisitions before making any investment decisions.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
